Profound Medical Corp. Announces Upsized Private Placement and Recent Closing of a $36‑Million Registered Direct Offering
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced that it has increased the size of the private placement it first disclosed on December 19, 2025. The company will now raise gross proceeds of up to US$6.45 million through the issuance of up to 921,428 common shares at a price of US$7.00 per share. Shares sold in this offering will be subject to a hold‑period of four months and one day from the closing date. The closing of the private placement is expected on or before December 30, 2025.
Profound has also confirmed the completion of a $36 million registered direct offering on December 23, 2025. The proceeds from that transaction were earmarked for use in expansion of sales and marketing, working capital needs, research and development, strategic transactions, and general corporate purposes. The company stated that no securities will be sold under the offering to United States purchasers, and that the press release is not an offer to sell or a solicitation to buy such securities in any jurisdiction where such an offer would be unlawful prior to qualification or registration under applicable securities laws.
The company’s current share price, as of December 22, 2025, stood at CAD 10.04, within a 52‑week range of CAD 5.23 to CAD 11.45. With a market capitalization of CAD 302.84 million and a price‑earnings ratio of ‑5.43, Profound remains a small‑cap player focused on localized prostate cancer treatments. The additional capital is expected to support the company’s growth strategy and strengthen its product pipeline in the health‑care equipment and supplies sector.
